Alvotech's Valuation Puzzle: A Deep Dive After a Year of Steep Losses and Recent Gains
Biosimilars developer Alvotech (NASDAQ: ALVO) presents a complex picture for investors, with recent short-term share price gains starkly contrasted by a punishing 57% decline over the past year. As the stock trades at a significant discount to some analyst targets, the market debates whether this signals a prime opportunity or reflects deeper, unresolved challenges.